Availability for Licensing

Government-Owned Inventions; For Further Information Contact: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR Part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301–435–4632; fax: 301–402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Use of Cysteamine to Treat Metastatic Cancer

Description of Technology: Cysteamine is an aminothiol and anti-oxidant that has potential for the treatment of radiation sickness, neurological disorders and cancer. Cysteamine has FDA approval for use in humans, and produces few side-effects as a natural degradation product of an essential amino acid. It is mostly used for treatment of cystinosis. The inventors on this technology have demonstrated that cysteamine also suppresses the activity of matrix metalloproteinases (MMPs). Because MMPs have been implicated in tumor invasion and metastasis, cysteamine has potential as an effective therapeutic for metastatic cancer. Administration of cysteamine was able to reduce invasion and metastasis in mouse xenograft tumor models and prolong survival of the mice without significant adverse side effects. This suggests that cysteamine could represent a novel therapeutic agent for treatment of metastatic cancer.

Potential Commercial Applications: Therapeutic for metastatic cancer as monotherapy or combined with other drugs.

Competitive Advantages:
- Cysteamine does not produce adverse side-effects when administered to humans.
- Cysteamine has already been approved for use in humans, providing a clearer path to clinical approval.

Development Stage:
- Pre-clinical.
- In vitro data available.
- In vivo data available (animal).

Inventors: Raj K. Puri and Bharat Joshi (CBER/FDA).


Related Technologies:
- HHS Reference No. E–027–2013/0—Canadian Application No. 2813514

Potential Commercial Applications:
- Surgery.
- Suturing.
- Catheterization.
- Cardiac valve repair.

Competitive Advantages:
- Formable suturing.
- Circumferential suturing.
- Flexible.
- Easy to use.

Development Stage: Prototype.

Inventors: Toby Rogers, Robert Lederman, Merdim Sommez, Dominique Franson, Onguur Kocaturk (all of NHLBI).
Peptide Inhibitors of Polo-like Kinase 1 (PLK1) Useful as Anti-cancer Therapeutics

Description of Technology: PLK1 is being studied as a target for cancer drugs. Many colon and lung cancers are caused by KRAS mutations. These cancers are dependent on PLK1. Inhibition of PLK1 allows for selective killing of cancer cells without harm to normal cells. The peptide derivatives available for licensing have achieved both good efficacy and enhanced bioavailability.

Potential Commercial Applications: Development of selective cancer therapeutics.

Competitive Advantages: Enhanced bioavailability and higher binding efficacy over existing peptide PLK1 ligands.

Development Stage: Early-stage.

Inventors: Terrence R. Burke, Fa Liu, Wen-Jian Qian, Jung-Eun Park, Kyung S. Lee (all of NCI).

Publications:


Licensing Contact: Patrick McCue, Ph.D.; 301–435–5560; mccuepat@mail.nih.gov.

Polymeric Silicone Hydrogel Vessel Mimetics for Cell Culturing

Description of Technology: The invention pertains to high oxygen diffusivity silicone hydrogel support structures that mimic tissue vasculature (e.g., capillary bed). Phototographic methods are used to construct mimetic silicone hydrogel pillars that have, for example, a 20:1 height to diameter ratio. Advantageously, these mimetic silicone hydrogels diffuse oxygen from the bottom chamber to the cells cultured on the surface at near physiological rates (60 times that of water). Uses of these mimetics include 2–D screening for chemotherapeutic compounds and growth of tissue for grafting.

Potential Commercial Applications: Tissue engineering.

Simulation of physiological growth conditions.

Competitive Advantages: High oxygen diffusivity.

Development Stage: Prototype.

Pilot.

In vitro data available.

Inventors: Chandan Das (NCI), Ashley Jaeger (CIT), Thomas Pohida (CIT), Randally Burt (CIT), Philip McQueen (CIT), Nicole Morgan (NIBIB), Michael Gottesman (NCI).

Intellectual Property:


Licensing Contact: Michael Shmilovich; 301–435–5019; shmilovm@mail.nih.gov.

Co-Transcriptional Assembly of Modified RNA Nanoparticles

Description of Technology: A method is provided for generating RNA nanoparticles having modified nucleotides and/or having increased nuclease resistance where the RNA nanoparticles are formed co-transcriptionally by T7 RNA polymerase in the presence of manganese ions.

Potential Commercial Applications: Inexpensive and efficient method of producing chemically modified RNA nanoparticles for diagnostic or therapeutic applications.

Competitive Advantages:

Overcomes the cost and size limitations of solid-phase RNA synthesis.

Allows complexity of RNA nanoparticles production.

Increases retention time of RNA nanoparticles.

Development Stage: Early-stage.

In vitro data available.

Inventors: Bruce A. Shapiro (NCI), Kirill Afonin (NCI), Maria Kiseleva (NCI), Mikhail Kashlev (NCI), Luc Jaeger (Univ California, Santa Barbara), Wade Grabow (Univ California, Santa Barbara).

Publications:


Related Technologies:


Licensing Contact: John Stansberry; 301–435–5236; stansbej@mail.nih.gov.
Collaborative Research Opportunity:
The NCI Center for Cancer Research Nanobio-
ology is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate or
commercialize diagnostic or therapeutic RNA nanoparticles. For collaboration
opportunities, please contact John
Hewes, Ph.D. at hewes@mail.nih.gov.

Dated: July 12, 2013.

Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

National Institutes of Health

Notice of Kidney Interagency
Coordinating Committee Meeting

SUMMARY: The Kidney Interagency
Coordinating Committee (KICC) will
hold a meeting on September 27, 2013,
about interagency collaboration to
improve outcomes in Chronic Kidney
Disease (CKD). The meeting is open to
the public.

DATES: The meeting will be held on
September 27, 2013, 9 a.m. to 12 p.m.
Individuals wanting to present oral
comments must notify the contact
person at least 10 days before the
meeting date.

ADDRESSES: The meeting will be held at
the Natcher Conference Center (Building
45), on the NIH Campus at 8600
Rockville Pike, Bethesda, MD 20894.

FOR FURTHER INFORMATION CONTACT:
For further information concerning this
meeting, contact Dr. Andrew S. Narva,
Executive Secretary of the Kidney
Interagency Coordinating Committee,
National Institute of Diabetes and
Dietetic and Kidney Diseases, 31
Center Drive, Building 31A, Room
9A26, MSC 2560, Bethesda, MD 20892–
2560, telephone: 301–594–8864; FAX:
301–480–0243; email:
nkdep@info.niddk.nih.gov.

SUPPLEMENTARY INFORMATION: The KICC,
chaired by the National Institute of
Diabetes and Digestive and Kidney
Diseases (NIDDK), comprises members of the Department of Health and Human
Services and other federal agencies that
support kidney-related activities,
facilitates cooperation, communication,
and collaboration on kidney disease
among government entities. KICC
meetings, held twice a year, provide an
opportunity for Committee members to
learn about and discuss current and
future kidney programs in KICC member
organizations and to identify
opportunities for collaboration. The
September 27, 2013 KICC meeting will
focus on interagency collaboration to
improve outcomes in CKD.

Any member of the public interested in
presenting oral comments to the
Committee should notify the contact
person listed on this notice at least 10
days in advance of the meeting.

Dated: July 8, 2013.

Camille Hoover,
Executive Officer, National Institute of
Diabetes and Digestive and Kidney Diseases,
National Institutes of Health.

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of
Closed Meetings

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.

Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Immune Mechanism.

Date: July 30, 2013.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant
applications.

Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).

Contact Person: Scott Jakes, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4108,
MSC 7812, Bethesda, MD 20892, 301–495–
1506, jakesse@mail.nih.gov.

This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.

Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA–OD–
13–005: Restoration of New Investigator Pilot
Projects Adversely Affected by Hurricane
Sandy.

Date: August 14, 2013.

Time: 1:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant
applications.

Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).

Contact Person: Weihua Luo, MD, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5114,
MSC 7854, Bethesda, MD 20892, (301) 435–
1170, luowcsr.nih.gov.

Name of Committee: Center for Scientific
Review Special Emphasis Panel; Vascular
Hematology.

Date: August 14, 2013.

Time: 2:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant
applications.

Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).

Contact Person: Bukhtiar H Shah, DVM,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4120,
MSC 7802, Bethesda, MD 20892, 301–806–
7314, shahbbcsr.nih.gov.

(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)

Dated: July 15, 2013.

Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.

[FR Doc. 2013–17320 Filed 7–18–13; 8:45 am]

BILLING CODE 4140–01–P